Manufacturing company Nordson (NASDAQ:NDSN) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 12.1% year on year to $741.5 million. Its non-GAAP profit of $2.73 per share was 3.5% above analysts’ consensus estimates.
Is now the time to buy NDSN? Find out in our full research report (it’s free).
Nordson (NDSN) Q2 CY2025 Highlights:
- Revenue: $741.5 million vs analyst estimates of $722.2 million (12.1% year-on-year growth, 2.7% beat)
- Adjusted EPS: $2.73 vs analyst estimates of $2.64 (3.5% beat)
- Adjusted EBITDA: $238.5 million vs analyst estimates of $230.1 million (32.2% margin, 3.7% beat)
- Operating Margin: 25.3%, in line with the same quarter last year
- Organic Revenue rose 2.1% year on year vs analyst estimates of flat growth (144.6 basis point beat)
- Market Capitalization: $12.07 billion
StockStory’s Take
Nordson’s second quarter was marked by strong demand in its Advanced Technology Solutions and Medical and Fluid Solutions segments, which helped the company surpass Wall Street expectations for both revenue and non-GAAP earnings per share. Management credited the ongoing integration of the Atrion acquisition as a key factor in expanding the medical product portfolio, particularly in proprietary fluid delivery and cardiovascular solutions. CEO Sundaram Nagarajan pointed to operational execution and sustained commercial momentum in core end markets as drivers of profit improvement and free cash flow, stating, “This operational performance reflects solid execution of the integration plan as well as the ongoing deployment of NBS Next.”
Looking forward, Nordson’s outlook is shaped by anticipated continued strength in Advanced Technology Solutions, normalization in medical device demand, and stabilization in select industrial markets. Management believes secular drivers—such as increased demand for semiconductor packaging, the aging population, and a shift to noninvasive medical procedures—will support growth, but acknowledged that uncertainty remains in the broader trade environment. Nagarajan indicated, “Our growth framework ensures new products are a growing source of organic growth and competitive advantage,” while cautioning that ongoing trade policy shifts and customer order timing could influence results in the coming quarters.
Key Insights from Management’s Remarks
Management attributed the quarter’s outperformance to robust growth in advanced electronics, successful integration of recent acquisitions, and focused execution in dynamic end markets.
- Advanced Technology Solutions momentum: The segment delivered double-digit organic sales growth, driven by demand for electronics dispense products and measurement systems, especially in Asia-Pacific. Management highlighted that repositioning the product portfolio and regional manufacturing, along with short lead times, enabled Nordson to capture new opportunities as supply chains shifted.
- Atrion acquisition impact: The Atrion medical portfolio added significantly to revenue and profitability, with accretive earnings contributions arriving a year ahead of initial expectations. Management emphasized that the integration accelerated operational efficiencies and expanded Nordson’s proprietary offering in medical infusion and cardiovascular markets.
- Medical segment normalization: After several quarters of inventory destocking, the medical fluid component business returned to high single-digit growth, and interventional solutions stabilized. Management believes the core medical business is on track for normal organic growth, supported by underlying trends like population aging and demand for less invasive procedures.
- Industrial Precision Solutions stabilization: While demand remained weak for polymer processing and automotive-related coatings, resilience in packaging, nonwoven, and precision agriculture applications helped mitigate the impact. Management noted that certain segments appear to have hit their trough, with expectations for sequential improvement as market conditions stabilize.
- Operational excellence and cash flow: The quarter featured record free cash flow, driven by sustained improvements in working capital management. This allowed for continued debt reduction, share repurchases, and ongoing investment in new product development, reflecting Nordson’s balanced capital deployment strategy.
Drivers of Future Performance
Nordson expects future performance to depend on new product adoption in semiconductors and medical, as well as recovering demand in core industrial markets.
- Growth in semiconductor packaging: Management expects continued momentum in electronics-related applications, particularly as Nordson’s solutions support advanced semiconductor packaging for artificial intelligence and cloud computing. The company is investing in R&D and sees opportunities as customers redesign supply chains to mitigate tariff risks.
- Medical device pipeline and market trends: With the normalization of inventory levels, the medical segment is positioned for high single-digit organic growth. Secular trends such as population aging and a shift toward noninvasive procedures are expected to drive demand, supported by recent product launches and a healthy pipeline.
- Macroeconomic and trade uncertainties: While management is optimistic about sequential improvement in industrial precision markets, it cautioned that ongoing volatility in global trade policy and customer capital spending cycles could affect order timing and growth rates. Targeted restructuring is expected to yield annual cost benefits, but near-term variability remains a risk.
Catalysts in Upcoming Quarters
In the coming quarters, our analysts will monitor (1) new product adoption rates in semiconductor and medical device applications, (2) the pace of recovery in industrial precision and polymer processing end markets, and (3) the impact of ongoing restructuring and portfolio optimization, including the divestiture of contract manufacturing. The trajectory of global trade policy and customer capital spending will also be key variables to watch.
Nordson currently trades at $221.35, up from $213.51 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
Stocks That Trumped Tariffs
Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.
Take advantage of the rebound by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.